Nesirtide, Safety and Efficacy: A Review
The Internet Journal of Cardiovascular Research · 2008
DOI: 10.5580/236c ↗At a glance
Journal article in The Internet Journal of Cardiovascular Research, 2008.
Abstract (original language)
Nesiritide, a recombinant form of human B-type natriuretic peptide is the first new parenteral agent to gain approval from FDA for acute decompensated heart failure in more than a decade. Although Nesiritide has been well studied in many trials and has been shown to be safe and effective, a recent meta-analysis report of increased 30 day mortality and worsening of renal function has created controversies with the use of nesiritide. The problems intrinsic to these meta-analyses were a heterogeneous patient population, enrolled in randomized controlled fashion and none of these trials were designed or powered to assess mortality risk. Until additional therapeutic trials are conducted, use of nesiritide should be based on clinical and hemodynamic improvement but at the same time it is imperative to use nesiritide only at approved doses and for approved duration which might minimize the risk of increased mortality and renal impairment.
Cite
APA
(2008). Nesirtide, Safety and Efficacy: A Review. The Internet Journal of Cardiovascular Research. https://doi.org/10.5580/236c
Vancouver
Nesirtide, Safety and Efficacy: A Review. The Internet Journal of Cardiovascular Research. 2008. doi:10.5580/236c
BibTeX
@article{euvimed2008,
title = {Nesirtide, Safety and Efficacy: A Review},
journal = {The Internet Journal of Cardiovascular Research},
year = {2008},
doi = {10.5580/236c}
}
EUVIMED